Colostrum From MERS-CoV Seropositive Camels for SARS-CoV-2 Infection - a Placebo-controlled Randomized Trial.

Colostrum From MERS-CoV Seropositive Camels for SARS-CoV-2 Infection - From Lab to Human- a Placebo Controlled Randomized Trial.

The study aims to study the efficacy of colostrum from MERS-CoV-positive camels applied as a nasal spray to COVID-19 patients for treatment and prevention of SARS-CoV-2 infection. This study will compare the usage of colostrum to placebo.

Inclusion Criteria:

• Age over 18 years.
• Laboratory-proven infection with COVID-19 using PCR or another approved kit
• Hospitalized / community setting-at low-moderate clinical risk according to the NEWS-2 scale with a score of 0-10.
• Onset of symptoms up to 7 days before inclusion
• Can sign informed consent
• Willingness and ability to participate in research

Exclusion Criteria:

• Pregnant women or lactating
• Lack of judgment (psychiatric disorder or dementia)
• Immunosuppressed - HIV with CD4 below 500, chemotherapy, steroids - more than 5 mg per day, solid organ transplants, bone marrow transplants, active hematological or oncological malignancies, biological therapy
• Neutropenia (less than 2000 neutrophils per cubic meter) or thrombocytopenia (platelet count less than 50000 per cubic meter).
• Acute or chronic sinusitis.
• Nasal polyps or any pathology in the nasal cavity
• Cystic fibrosis
• Significant disturbance in liver functions (AST/ALT more than 5 times the ULN)
• Significant renal dysfunction (GFR lower than 30 ml per minute)
• Known allergy to colostrum or cow's milk
• Use of another study drug